Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Executive Summary
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.
You may also be interested in...
Lilly Calls Time On UK Neuroscience Research Center
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
